Daniel Brennan, MD

My research interests related to diabetes and metabolism are related to the incidence and prevention of New Onset Diabetes After Transplantation (NODAT) and also islet transplantation. My funded research project, Clinical trial NIS01 (ITN005CT), opened in May 2001 under an IND sponsored by the Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases (NIAID. This trial was supported by the Immune Tolerance Network. The study was a 3-year, 9-center, single-arm, phase I, open-label study of islet cell transplantation in type 1 diabetes mellitus (T1DM). Thirty six participants were enrolled and treated in this trial. The current protocol ITN040CT provides a mechanism to supply immunosuppressive medications for the continued support of transplanted islet cell function to those participants enrolled at U.S sites who have evidence of continued insulin production as demonstrated by C-peptide production. The primary objective of this protocol is to provide immunosuppressive medications to participants previously enrolled in NIS01 who continue to have beta cell function as shown by detectable C-peptide. The insulin, C-peptide and glucose levels are analyzed by the immunoassay core of the DRTC.